Captrust Financial Advisors Sells 4,055 Shares of Moderna, Inc. (NASDAQ:MRNA)

Captrust Financial Advisors reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 48.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,387 shares of the company’s stock after selling 4,055 shares during the quarter. Captrust Financial Advisors’ holdings in Moderna were worth $293,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Public Sector Pension Investment Board increased its position in shares of Moderna by 18.0% in the third quarter. Public Sector Pension Investment Board now owns 16,380 shares of the company’s stock valued at $1,095,000 after acquiring an additional 2,500 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after purchasing an additional 19,819 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Moderna by 17.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 157,774 shares of the company’s stock valued at $10,544,000 after purchasing an additional 23,631 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Moderna during the 3rd quarter valued at approximately $4,883,000. Finally, Townsquare Capital LLC lifted its holdings in Moderna by 42.7% in the 3rd quarter. Townsquare Capital LLC now owns 5,288 shares of the company’s stock worth $353,000 after buying an additional 1,583 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Activity

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,379 shares of company stock valued at $158,195 over the last three months. Insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MRNA. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Jefferies Financial Group decreased their price objective on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. UBS Group cut their target price on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research note on Monday, November 18th. Finally, TD Cowen cut their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $79.50.

Moderna Stock Performance

Shares of MRNA opened at $41.83 on Friday. The company has a market cap of $16.10 billion, a price-to-earnings ratio of -7.19 and a beta of 1.58. The business’s fifty day simple moving average is $48.26 and its two-hundred day simple moving average is $83.67. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period last year, the company earned ($1.39) EPS. Research analysts anticipate that Moderna, Inc. will post -9.3 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.